Phase 2 N=7 Fenfluramine in CDKL5 Deficiency Disorder (CDD)
CDD
Primary: Change From Baseline in Median Monthly Convulsive Seizure Frequency — 88.429 Number of monthly seizures
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Split-tattoo Study Comparing the Safety and Efficacy of 670nm Picosecond Laser Versus 755 nm for Tattoo Removal
Tattoo Removal
Primary: Degree of Tattoo Clearing as Assessed by the Investigator (Physician's Global Assessment of Improvement) — 4; 4; 4 score on a scale
Phase 2 N=127 Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Breast Cancer · HER2-negative Breast Cancer · HER2-positive Breast Cancer
Primary: Progression Free Survival — 95; 93 percentage of participants
Phase 3 N=147 A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis
Trichomonas Infection
Primary: Microbiological Cure at the TOC Visit — 59; 1 Participants
Phase 1 N=12 Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants
Healthy Participants
Primary: Maximum Plasma Concentration (Cmax) of Midazolam When Administered Alone and With PF-07321332/Ritonavir — 9.812; 36.18 ng/mL
N/A N=8 An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders
Autism Spectrum Disorders · Pervasive Developmental Disorders · ASD
Primary: Change in ASD Symptoms Social Responsiveness Scales 2 (SRS-2) Scales From Baseline to Week 8 — -32.4 scores on a scale
Phase 2 N=241 Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines
Moderate to Severe Glabellar Frown Lines
Primary: Duration of Effect Defined as Time Between Treatment and Relapse to Baseline Status Assessed by the Investigator on the FWS — 175; 185; 210; 215 days — p== 0.881
Phase 2 N=91 Cognitive Enhancement Through Transcranial Laser Therapy
Healthy Participants · Mild Cognitive Impairment
Primary: Psychomotor Vigilance Task (PVT) — 341.89; 344.09; 331.11; 330.75 msec — p=0.79
Phase 2 N=127 A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
Relapsed or Refractory Solid Tumors
Primary: Objective Response Rate (ORR) At Week 16 Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO)…
N/A N=185 Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach
Neonatal Opiate Withdrawal Syndrome
Primary: Time From Birth Until Medically Ready for Discharge — 14.9; 8.2 days — p=<0.0001
Phase 2 N=463 Pilot Herniorrhaphy Study for Postoperative Analgesia
Postoperative Pain
Primary: Mean Summed Pain Intensity (SPI) Score — 83.71; 77.63; 95.24; 89.28 Units on a scale
Phase 3 N=1,124 A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection
Respiratory Syncytial Virus Infection Prevention
Primary: Cohorts 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs) — 273; 10; 276; 15 Participants
N/A N=20 Clinical Evaluation of the Safety and Performance of FRF for the Treatment and Reduction of Acne Scarring
Acne Scars - Mixed Atrophic and Hypertrophic
Primary: Subject Satisfaction — 3.5 units on a scale
N/A N=400 Talk Therapy by Phone to Promote Treatment for Alcohol Problems
Alcohol Use Disorder · Alcohol Abuse
Primary: Average Drinks Per Drinking Day — 5.5; 5.4 drinks per occasion — p=0.746
N/A N=65 NIRTRAKS Post-Market Study (NIRTRAKS)
de Novo Stenotic Lesions in Native Coronary Arteries
Primary: Target Vessel Failure — 15 percentage of TVF